Management Team

David Atkins is an accomplished global healthcare leader with global markets experience across a broad range of life sciences and healthcare disciplines, having gained deep experience in R&D, product development and commercialisation across biotech, medical device, IVD and data-driven solutions in all global markets. Over the last 30 years, David has held national, regional and global roles across the pharmaceutical, medical device and diagnostics sectors. David’s responsibilities have covered all functions from discovery research through to sales and marketing in most key geographies. He has valuable experience in start-up ventures, scale-ups, turnarounds and high-growth enterprises. He has held senior leadership roles in smaller businesses including Congenica (UK), Veridex (US) and Gene Shears (Australia), and larger global businesses including Johnson & Johnson and Danaher.

Andrea Steele is an independent Melbourne based lawyer who specialises in providing legal, regulatory and compliance advice to the Australian life sciences, healthcare, energy and renewable industries. Andrea’s key practice includes advising both listed and private companies, multinationals and government organisations on matters relating to the negotiation of complex commercial contracts, regulatory advice, major procurement, strategic collaborations and mergers and acquisitions. Andrea’s deep experience and practical insights are particularly appreciated by clients who seek her guidance on how to plan and execute these important projects.

Nir is an accomplished operational leader with over 25 years of experience in driving multidisciplinary teams toward successful product delivery across regulated and unregulated environments. His extensive experience spans the entire product lifecycle – from research to market adoption – across biotechnology, medical devices, defence, environment, telecommunication, and IT industries.

Nir has delivered transformative solutions in cancer diagnostics, COVID point-of-care diagnostics, IVF technologies, diabetes management, hematology, and advanced pathology lab automation systems. Having worked with industry leaders including Planet Innovation, Invetech, Grey Innovation Group and Agilent Technologies, as well as founding several successful businesses, Nir brings comprehensive operational expertise in building robust business capabilities across commercial operations, customer delivery, product development, and manufacturing establishment.

Jackson is an experienced life science and biotechnology leader with over 25 years of experience in driving diagnostic innovation and commercialisation. His extensive technical expertise in cancer, proteomics, and molecular biology has been instrumental in successfully implementing market strategies across blood banking, microbiology, and infectious disease diagnostics.

Jackson has demonstrated exceptional ability in guiding products through the complete lifecycle, from research and development through regulatory approvals to commercial success, with a proven track record of launching innovative diagnostic technologies across global markets including Australia, Asia, Europe, the UK, and the US.

Dr. Spaeth has worked with the previous owner of geneType™ since 2016. She is responsible for the development of clinical content and clinical rationale for the geneType™ product suite. With a focus on transposing our cutting-edge approach to disease risk modelling into effortless yet actionable genetic-integrated information for both clinicians and patients, she is a cross-functional team member.

Erika is involved in developing and executing commercial clinical research, pilot studies and managing academic research collaborations. She has wide experience in the high-complexity laboratory space from assay development to regulatory oversight of laboratory developed tests in the oncology, infectious disease and inherited disease space.

Todd is an accomplished business leader with extensive experience in driving organisational transformation and financial performance improvement. His strategic approach has consistently delivered significant business value across multiple sectors including technology, healthcare, and financial services.

Todd most recently served as CEO of AdNeo Limited (ASX: AD1), where he successfully led a comprehensive business turnaround. His leadership resulted in multi-million-dollar improvements in EBITDA and NPAT year-over-year, while securing a $2.6 million capital raise, completing the strategic acquisition of Oliver Grace, and expanding the company's US mentoring subsidiary by over 200%.